Document:

Document

Exhibit 4.2
DESCRIPTION OF SECURITIES

As of September 30, 2022, Golub Capital BDC 4, Inc., a Maryland corporation (“we,” “our,” “us” or the “Company”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.001 per share.

For purposes of this exhibit, references to “we,” “our” and “us” refer only to Golub Capital BDC 4, Inc. and not to any of its current or future subsidiaries and references to “subsidiaries” refer only to consolidated subsidiaries of and exclude any investments held by Golub Capital BDC 4, Inc. in the ordinary course of business which are not, under GAAP, consolidated on the financial statements of Golub Capital BDC 4, Inc. and its subsidiaries.
 
Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Annual Report on Form 10-K to which this Description of Securities is attached as an exhibit.
    
The following description is based on relevant portions of the Maryland General Corporation Law (the “MGCL”) and on our charter and bylaws, each of which is filed as an exhibit to our Annual Report on Form 10-K of which this Exhibit 4.2 is a part. This summary is not necessarily complete, and we refer you to the MGCL and our charter and bylaws for a more detailed description of the provisions summarized below.

Capital Stock

Our authorized stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 1,000,000 shares of preferred stock, par value $0.001 per share. There is currently no market for our common stock, and we can offer no assurances that a market for our shares will develop in the future. There are no outstanding options or warrants to purchase our stock. No stock has been authorized for issuance under any equity compensation plans. Under Maryland law, our stockholders generally are not personally liable for our debts or obligations.
 
The following are our outstanding classes of securities as of September 30, 2022:
 
																																							
	(1) Title of Class	 	(2) Amount
Authorized	 	 	(3) Amount Held
by us or for Our
Account	 	 	(4) Amount
Outstanding
Exclusive of
Amounts Shown
Under (3)	 
	Common Stock	 	 	200,000,000	 	 	 	—	 	 	 	4,628,404.940 		 
	Preferred Stock	 	 	1,000,000	 	 	 	—	 	 	 	—	 

 
Under our charter, our board of directors is authorized to classify and reclassify any unissued shares of stock into other classes or series of stock and authorize the issuance of shares of stock without obtaining stockholder approval. As permitted by the MGCL, our charter provides that our board of directors, without any action by our stockholders, can amend the charter from time to time to increase or decrease the aggregate number of shares of stock or the number of shares of stock of any class or series that we have authority to issue.
 
All shares of our common stock have equal rights as to earnings, assets, dividends and other distributions and voting and, when they are issued, will be duly authorized, validly issued, fully paid and nonassessable. Distributions are paid to the holders of our common stock if, as and when authorized by our board of directors and declared by us out of assets legally available therefor. Shares of our common stock have no preemptive, exchange, conversion or redemption rights and are freely transferable, except when their transfer is restricted by federal and state securities laws or by contract. In the event of our liquidation, dissolution or winding up, each share of our common stock would be entitled to share ratably in all of our assets that are legally available for distribution after we pay all debts and other liabilities and subject to any preferential rights of holders of our preferred stock, if any preferred stock is 
    1

outstanding at such time. Each share of our common stock is entitled to one vote on all matters submitted to a vote of stockholders, including the election of directors. Except as provided with respect to any other class or series of stock, the holders of our common stock will possess exclusive voting power. There is no cumulative voting in the election of directors, which means that holders of a majority of the outstanding shares of common stock can elect all of our directors, and holders of less than a majority of such shares will not be able to elect any directors.
 
Transfer and Resale Restrictions
 
We have sold and continue to offer shares of our common stock in a private placement in the United States under the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder, Regulation S under the Securities Act and other exemptions from the registration requirements of the Securities Act. Investors who acquire shares of our common stock in our private placement are required to complete, execute and deliver a subscription agreement and related documentation, which includes customary representations and warranties, certain covenants and restrictions and indemnification provisions. Additionally, such investors could be required to provide due diligence information for compliance with certain legal requirements. We, from time to time, engage placement or distribution agents and incur placement or distribution fees or sales commissions in connection with the private placement of our common stock in certain jurisdictions outside the United States. The cost of any such placement or distribution fees could be borne by an affiliate of the Adviser. We will not incur any such fees or commissions if our net proceeds received upon a sale of our common stock after such costs would be less than the net asset value per share of our common stock.

Prior to a Liquidity Event (as defined below), no transfer of capital commitments of investors in the private placement of our common stock or all or any portion of our investors’ shares of our common stock can be made without (a) registration of the transfer on our books and (b) our prior written consent. In any event, our consent can be withheld (1) if the creditworthiness of the proposed transferee, as determined by us in our sole discretion, is not sufficient to satisfy all obligations under the applicable subscription agreement or (2) unless, in the opinion of counsel satisfactory in form and substance to us:

•such transfer would not violate the Securities Act or any state (or other jurisdiction) securities or “blue sky” laws applicable to us or the shares to be transferred; and

•in the case of a transfer to:

◦an “employee benefit plan” as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that is subject to ERISA;
◦a “plan” described in Section 4975(e)(1) of the Code, that is subject to Section 4975 of the Code;
◦an entity that is, or is deemed to be, using (for purposes of ERISA or Section 4975 of the Code) “plan assets” to purchase or hold its investments; or
◦a person (including an entity) that has discretionary authority or control with respect to our assets or a person who provides investment advice with respect to our assets or an “affiliate” of such person,

such transfer would not be a “prohibited transaction” under ERISA or Section 4975 of the Code or cause all or any portion of our assets to constitute “plan assets” under ERISA or Section 4975 of the Code.

A “Liquidity Event” is defined as any of the following: (1) an initial public offering of our common stock or the listing of shares of our common stock on a national securities exchange or (2) a sale of all or substantially all of our assets to, or other liquidity event with, an entity for consideration of either cash and/or publicly listed securities of the acquirer, which potential acquirers may include business development companies, including business development companies affiliated with the Adviser, and entities that are not business development companies.

    2

In addition, prior to a registration of our shares sufficient to cause us to treat our shares as a “publicly-offered security” for purposes of the Plan Assets Regulation, we intend to limit investment by certain benefit plan investors so as to attempt to avoid our assets from being deemed to be “plan assets” for purposes of ERISA or Section 4975 of Internal Revenue Code of 1986, as amended (the “Code”).  We can reject any transfer of shares if such transfer could (i) cause all or any portion of the assets of the company to constitute “plan assets” under ERISA or Section 4975 of the Code or (ii) constitute or result in a non-exempt prohibited transaction under ERISA or Section 4975 of the Code, or a non-exempt violation of any law that is substantially similar to the prohibited transaction provisions of ERISA or Section 4975 of the Code.

Any person that acquires shares of our common stock in a transfer permitted under a subscription agreement is obligated to pay to us the appropriate portion of any amounts thereafter becoming due in respect of the capital commitment committed to be made by its predecessor in interest. An investor will remain liable for their capital commitments prior to the time, if any, when the purchaser, assignee or transferee of such shares, or fraction thereof, becomes a holder of such shares.

Furthermore, should there be an initial public offering of our common stock or listing of our common stock on a national securities exchange, holders of our common stock will be subject to lock-up restrictions pursuant to which they will be prohibited from selling shares of our common stock for a minimum of 180 days after the pricing of such initial public offering or the listing. The specific terms of this restriction and any other limitations on the sale of our common stock in connection with or following an initial public offering will be agreed in advance between our board of directors and the Adviser, acting on behalf of our investors, and the underwriters of the initial public offering or other similar institutions, acting on our behalf, in connection with a listing.
  
Provisions of the MGCL and Our Charter and Bylaws
 
Limitation on Liability of Directors and Officers; Indemnification and Advance of Expenses
 
The MGCL permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (a) actual receipt of an improper benefit or profit in money, property or services or (b) active and deliberate dishonesty established by a final judgment as being material to the cause of action. Our charter contains such a provision which eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law, subject to the requirements of the Investment Company Act of 1940, as amended (the “1940 Act”).
 
Our charter authorizes us, to the maximum extent permitted by the MGCL and subject to the requirements of the 1940 Act, to obligate us to indemnify, and to pay or reimburse reasonable expenses in advance of final disposition of a proceeding to, any present or former director or officer or any individual who, while a director or officer and at our request, serves or has served another corporation, partnership, joint venture, limited liability company, trust, employee benefit plan, or other enterprise as a director, officer, partner, member, manager or trustee, from and against any claim or liability to which that person could become subject or which that person incurs by reason of his or her service in any such capacity and to pay or reimburse their reasonable expenses in advance of final disposition of a proceeding.
 
Our bylaws obligate us, to the maximum extent permitted by the MGCL and subject to the requirements of the 1940 Act, to indemnify any present or former director or officer or any individual who, while a director or officer and at our request, serves or has served another corporation, partnership, joint venture, limited liability company, trust, employee benefit plan or other enterprise as a director, officer, partner, member, manager or trustee and who is made, or threatened to be made, a party to a proceeding by reason of his or her service in any such capacity from and against any claim or liability to which that person becomes subject or which that person incurs by reason of his or her service in any such capacity and, without requiring a preliminary determination of the ultimate entitlement to indemnification to pay or reimburse their reasonable expenses in advance of final disposition of a proceeding. Our charter and bylaws also permit us to indemnify and advance expenses to any person who served a predecessor of us in any of the capacities described above and any of our employees or agents or any employees or agents of our 
    3

predecessor. In accordance with the 1940 Act, we will not indemnify any person for any liability to which such person would be subject by reason of such person’s willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office.
 
The MGCL requires a corporation (unless its charter provides otherwise, which our charter does not) to indemnify a director or officer who has been successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made, or threatened to be made, a party by reason of his or her service in that capacity. The MGCL permits a corporation to indemnify its present and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they can be made, or threatened to be made, a party by reason of their service in those or other capacities unless it is established that (a) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (1) was committed in bad faith or (2) was the result of active and deliberate dishonesty, (b) the director or officer actually received an improper personal benefit in money, property or services or (c) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. However, under the MGCL, a Maryland corporation cannot indemnify for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received unless, in either case, a court orders indemnification, and then only for expenses. In addition, the MGCL permits a corporation to advance reasonable expenses to a director or officer upon the corporation’s receipt of (a) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification by the corporation and (b) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately determined that the standard of conduct was not met.
 
Election of Directors
 
Our bylaws provide that the affirmative vote of a majority of the total votes cast “for” or “against” a nominee for director at a duly called meeting of stockholders at which a quorum is present is required to elect a director in an uncontested election. In a contested election, directors are elected by a plurality of the votes cast at a meeting of stockholders duly called and at which is a quorum is present. Under our bylaws, our board of directors is able to amend the bylaws to alter the vote required to elect directors.
 
Classified Board of Directors
 
Our board of directors is divided into three classes of directors serving staggered three-year terms, with the term of office of only one of the three classes expiring each year. At each annual meeting of stockholders, directors of the class of directors whose term expires at such meeting will be elected to hold office for a term expiring at the third succeeding annual meeting of stockholders following the meeting at which they were elected and until their successors are duly elected and qualified. A classified board can render a change in control of us or removal of our incumbent management more difficult. We believe, however, that the longer time required to elect a majority of a classified board of directors helps to ensure the continuity and stability of our management and policies.
 
Number of Directors; Removal; Vacancies
 
Our charter and bylaws provide that the number of directors will be set only by the board of directors. Our bylaws provide that a majority of our entire board of directors can at any time increase or decrease the number of directors. However, unless our bylaws are amended, the number of directors can never be less than the minimum number required by the MGCL nor more than 12. We have elected to be subject to the provision of Subtitle 8 of Title 3 of the MGCL regarding the filling of vacancies on the board of directors. Accordingly, except as provided by the board of directors in setting the terms of any class or series of preferred stock, any and all vacancies on the board of directors, including a vacancy resulting from an enlargement of the board of directors, can be filled only by vote of a majority of the directors then in office, even if the remaining directors do not constitute a quorum, and any director elected to fill a vacancy will serve for the remainder of the full term of the directorship in which the vacancy occurred and until a successor is elected and qualifies, subject to any applicable requirements of the 1940 Act. Our charter provides that a director can be removed only for cause, as defined in our charter, and then only by the 
    4

affirmative vote of at least two-thirds of the votes entitled to be cast in the election of directors. The limitations on the ability of our stockholders to remove directors and fill vacancies could make it more difficult for a third-party to acquire, or discourage a third-party from seeking to acquire, control of us.

Action by Stockholders
 
Under the MGCL, stockholder action can be taken only at an annual or special meeting of stockholders or by unanimous written consent in lieu of a meeting (unless the charter provides for stockholder action by less than unanimous consent, which our charter does not). These provisions, combined with the requirements of our bylaws regarding the calling of a stockholder-requested meeting of stockholders discussed below, can have the effect of delaying consideration of a stockholder proposal until the next annual meeting.
 
Advance Notice Provisions for Stockholder Nominations and Stockholder Proposals
 
Our bylaws provide that with respect to an annual meeting of stockholders, nominations of persons for election to the board of directors and the proposal of business to be considered by stockholders can be made only (1) by or at the direction of the board of directors, (2) pursuant to our notice of meeting or (3) by a stockholder who was a stockholder of record at the time of provision of notice, at the record date and at the time of the meeting, who is entitled to vote at the meeting and who has complied with the advance notice procedures of the bylaws. With respect to special meetings of stockholders, only the business specified in our notice of the meeting can be brought before the meeting. Nominations of persons for election to the board of directors at a special meeting can be made only (1) by or at the direction of the board of directors or (2) provided that the special meeting has been called in accordance with our bylaws for the purposes of electing directors, by a stockholder who was a stockholder of record at the time of provision of notice, at the record date and at the time of the meeting, who is entitled to vote at the meeting and who has complied with the advance notice provisions of the bylaws.
 
The purpose of requiring stockholders to give us advance notice of nominations and other business is to afford our board of directors a meaningful opportunity to consider the qualifications of the proposed nominees and the advisability of any other proposed business and, to the extent deemed necessary or desirable by our board of directors, to inform stockholders and make recommendations about such qualifications or business, as well as to provide a more orderly procedure for conducting meetings of stockholders. Although our bylaws do not give our board of directors any power to disapprove stockholder nominations for the election of directors or proposals recommending certain action, they could have the effect of precluding a contest for the election of directors or the consideration of stockholder proposals if proper procedures are not followed and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of directors or to approve its own proposal without regard to whether consideration of such nominees or proposals might be harmful or beneficial to us and our stockholders.
 
Calling of Special Meetings of Stockholders
 
Our bylaws provide that special meetings of stockholders can be called by our board of directors and certain of our officers. Additionally, our bylaws provide that, subject to the satisfaction of certain procedural and informational requirements by the stockholders requesting the meeting, a special meeting of stockholders will be called by the secretary of the corporation upon the written request of stockholders entitled to cast not less than a majority of all the votes entitled to be cast at such meeting.
 
Approval of Extraordinary Corporate Action; Amendment of Charter and Bylaws
 
Under the MGCL, a Maryland corporation generally cannot dissolve, amend its charter, merge, convert, transfer all or substantially all of its assets, engage in a share exchange, consolidate or engage in similar transactions outside the ordinary course of business, unless the action is declared advisable by the board of directors and approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter. However, a Maryland corporation can provide in its charter for approval of these matters by a lesser percentage, but not less than a majority of all the votes entitled to be cast on the matter. Our charter provides for approval of these 
    5

matters, by the affirmative vote of the holders of a majority of the total number of shares entitled to vote on the matter.
 
Our bylaws provide that the board of directors will have the exclusive power to adopt, alter or repeal any provision of our bylaws and to make new bylaws.

No Appraisal Rights
 
Except with respect to appraisal rights arising in connection with the Maryland Control Share Acquisition Act discussed below, as permitted by the MGCL, our charter provides that stockholders will not be entitled to exercise appraisal rights.
 
Control Share Acquisitions
 
The Control Share Acquisition Act provides that control shares of a Maryland corporation acquired in a control share acquisition have no voting rights except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter. Shares owned by the acquirer, by officers or by directors who are employees of the corporation are excluded from shares entitled to vote on the matter. Control shares are voting shares of stock which, if aggregated with all other shares of stock owned by the acquirer or in respect of which the acquirer is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquirer to exercise voting power in electing directors within one of the following ranges of voting power:
 
									
	 	•	one-tenth or more but less than one-third;

 
									
	 	•	one-third or more but less than a majority; or

 
									
	 	•	a majority or more of all voting power.

 
The requisite stockholder approval must be obtained each time an acquirer crosses one of the thresholds of voting power set forth above. Control shares do not include shares the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval. A control share acquisition means the acquisition of control shares, subject to certain exceptions.
 
A person who has made or proposes to make a control share acquisition can compel the board of directors of the corporation to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. The right to compel the calling of a special meeting is subject to the satisfaction of certain conditions, including an undertaking to pay the expenses of the meeting. If no request for a meeting is made, the corporation can itself present the question at any stockholders meeting.
 
If voting rights are not approved at the meeting or if the acquiring person does not deliver an acquiring person statement as required by the statute, then the corporation can repurchase for fair value any or all of the control shares, except those for which voting rights have previously been approved. The right of the corporation to repurchase control shares is subject to certain conditions and limitations, including, as provided in our bylaws, compliance with the 1940 Act. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the date of the last control share acquisition by the acquirer or of any meeting of stockholders at which the voting rights of the shares are considered and not approved. If voting rights for control shares are approved at a stockholders meeting and the acquirer becomes entitled to vote a majority of the shares entitled to vote, all other stockholders can exercise appraisal rights. The fair value of the shares as determined for purposes of appraisal rights cannot be less than the highest price per share paid by the acquirer in the control share acquisition.
 
    6

The Control Share Acquisition Act does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction or (b) to acquisitions approved or exempted by the charter or bylaws of the corporation.
 
Our bylaws contain a provision exempting from the Control Share Acquisition Act any and all acquisitions by any person of our shares of stock. There can be no assurance that such provision will not be amended or eliminated at any time in the future to the extent permitted by the 1940 Act.
 
Business Combinations
 
Under the MGCL, “business combinations” between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as:
 
									
	 	•	any person who, directly or indirectly, beneficially owns 10% or more of the voting power of the corporation’s shares; or

 
									
	 	•	an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was, directly or indirectly, the beneficial owner of 10% or more of the voting power of the then outstanding voting stock of the corporation.

 
A person is not an interested stockholder under this statute if the board of directors approved in advance the transaction by which he otherwise would have become an interested stockholder. However, in approving a transaction, the board of directors can provide that its approval is subject to compliance, at or after the time of approval, with any terms and conditions determined by the board.
 
After the five-year prohibition, any business combination between the corporation and an interested stockholder generally must be recommended by the board of directors of the corporation and approved by the affirmative vote of at least:
 
									
	 	•	80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and

									
	 	•	two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder.

 
These super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under the MGCL, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares.
 
The statute permits various exemptions from its provisions, including business combinations that are exempted by the board of directors before the time that the interested stockholder becomes an interested stockholder. Our board of directors can adopt a resolution that any business combination between us and any other person is exempted from the provisions of the Business Combination Act, provided that the business combination is first approved by the board of directors, including a majority of the directors who are not interested persons as defined in the 1940 Act. This resolution, however, can be altered or repealed in whole or in part at any time. The Maryland Business Combination Act discourages third parties from trying to acquire control of us and increase the difficulty of consummating such an offer.
 
    7

Conflict with 1940 Act
 
Our bylaws provide that, if and to the extent that any provision of the MGCL, including the Control Share Acquisition Act (if we amend our bylaws to be subject to such Act) and the Business Combination Act, or any provision of our charter or bylaws conflicts with any provision of the 1940 Act, the applicable provision of the 1940 Act will control.

    8EX-10.1

 Exhibit 10.1 

EXECUTIVE TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENT 

This Executive Transition, Separation, and Release of Claims Agreement (the “Agreement”) is made as of December 7, 2022
(the “Effective Date”) by and between Inozyme Pharma, Inc. (the “Company”) and Henric Bjarke (the “Executive”) (together, the “Parties”). 

WHEREAS, the Company and the Executive are parties to that certain Letter Agreement dated as of June 30, 2020 (the
“Letter Agreement”), under which the Executive currently serves as Senior Vice President and Chief Operating Officer of the Company; 

WHEREAS, the Parties desire to establish mutually agreeable terms for the Executive’s transition and separation from employment
with the Company; and 
 WHEREAS, the Parties agree that the payments, benefits and rights set forth in this Agreement shall be the
exclusive payments, benefits and rights due to the Executive in connection with his transition and separation from employment with the Company; 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 Separation Date; Resignation from Position(s); Transition Period(a) The Executive’s
effective date of separation from employment with the Company will be December 31, 2022 (the “Separation Date”). The Executive hereby resigns as of the Separation Date from his position as Senior Vice President and Chief
Operating Officer of the Company and from any and all other positions he holds as an officer of the Company or as an officer or director of any subsidiary or affiliate of the Company, and further agrees to execute and deliver any documents
reasonably necessary to effectuate such resignations, as requested by the Company. Notwithstanding the foregoing, the Company retains the right to immediately terminate the Executive’s employment prior to December 31, 2022 for Cause (as
defined in the Letter Agreement, except that, for purposes of this Agreement, references in such definition to “the Letter Agreement” shall be construed as referencing this Agreement) and, in such event, or in the event that the Executive
resigns his employment for any reason prior to December 31, 2022, the date of such earlier termination shall become the Separation Date. 

(b) As of the Effective Date, the Letter Agreement will terminate and be of no further force or effect; provided, however, for the avoidance of
doubt, that the Executive’s Restrictive Covenant Agreement (as defined in the Letter Agreement) shall remain in full force and effect both during the Transition Period (as defined below) and thereafter. 

(c) The period between the Effective Date and the Separation Date will be a transition period (the “Transition Period”).
During the Transition Period, the Executive will continue to perform his regular duties as Senior Vice President and Chief Operating Officer on a full-time basis consistent with his position and use his best efforts to professionally, timely and
cooperatively perform such duties, as well as such additional transition duties as may be requested by and at the direction of the Company or its Board of Directors (the “Board”) (including, without limitation, assisting with

  
 1 

 
the transition of the Executive’s duties and responsibilities to other individuals). During the Transition Period, the Executive will continue to receive his current base salary, to
participate in the Company’s benefit plans (pursuant to the terms and conditions of such plans) and to be entitled to paid time off in accordance with Company policy. For the avoidance of doubt, the Executive will be required to continue to
perform his duties primarily in the Company’s offices in Massachusetts, and, in addition, the Company agrees that it will reimburse the Executive for reasonable travel expenses associated with traveling between his home and the Company’s
offices in Massachusetts, with such travel and reimbursement to be consistent with Company policy, and will permit the Executive to stay in the Company’s corporate apartment for reasonable periods of time during such visits. 

(d) In connection with the Executive’s separation from employment, the Executive shall be paid, in accordance with applicable law and the
Company’s regular payroll practices, all unpaid base salary earned through the Separation Date, any amounts for accrued unused paid time off to which the Executive is entitled through such date in accordance with Company policy, and
reimbursement of any properly incurred unreimbursed business expenses incurred through such date (together, the “Accrued Obligations”). As of the Separation Date, all salary payments from the Company will cease and any benefits the
Executive had as of such date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law or as otherwise specifically set forth in this Agreement. For the avoidance of doubt, in the event
of the Executive’s termination for Cause prior to December 31, 2022, or if the Executive resigns his employment for any reason prior to December 31, 2022, the Executive will receive only the Accrued Obligations, and will not be
eligible for or entitled to the Consideration (as defined below) or any other payments or benefits following such termination. 
  

	2.	 Consideration – In consideration of the Executive’s entering into and abiding by the
commitments and obligations set forth in this Agreement, and provided the Executive (i) signs and returns this Agreement on the Effective Date, (ii) continues employment through the Separation Date in accordance with the terms hereof,
(iii) does not resign for any reason and is not terminated for Cause by the Company, (iv) signs and returns the Additional Release of Claims attached to this Agreement as Attachment A (the “Additional Release”) no earlier
than the Separation Date but by the later of the Separation Date and the twenty-second (22nd) day after the Receipt Date (as defined below), and does not timely revoke such Additional Release (as
described therein), and (v) complies with the terms of this Agreement, the Additional Release, and the Restrictive Covenant Agreement, the Company will provide the Executive with the following consideration (the
“Consideration”), the payment of which shall be subject to the provisions of Appendix A to the Letter Agreement (except that, for purposes of this Agreement, references in such Appendix A to the “Letter Agreement” shall be
construed as referencing this Agreement): 

 (a) Severance Benefits – The Company will pay to the Executive as
severance pay three hundred forty-three thousand nine hundred sixty-one dollars and eleven cents ($343,961.11) less all applicable taxes and withholdings (an amount equivalent to nine (9) months of the
Executive’s current base salary). This severance pay will be paid in substantially equal installments in accordance with the Company’s regular payroll practices, and payments shall begin in the Company’s first payroll period following
July 1, 2023 or, if later, the date that Executive has a “separation from service” with the Company (as defined under Section 409A of the Internal Revenue Code and the guidance issued thereunder); provided, however, that if the
Consultation Period (as defined in the Consulting Agreement referenced below) is terminated prior to the Expiration Date (as defined in the Consulting Agreement), payments shall begin in the Company’s first payroll period following such
termination of the Consultation Period. In addition, should the Executive timely elect and be eligible to continue receiving group medical coverage pursuant to 

  
 2 

	 	
the “COBRA” law, and so long as the Company can provide such benefit without violating the nondiscrimination requirements of applicable law, the Company will continue to pay the premium
for such coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage until the earlier of (x) nine (9) months following the Separation Date, and (y) the date upon which the
Executive commences full-time employment (or employment that provides the Executive with eligibility for healthcare benefits substantially comparable to those provided by the Company) with an entity other than the Company. If applicable, the
remaining balance of any premium costs shall be timely paid by the Executive on a monthly basis for as long as, and to the extent that, the Executive remains eligible for and elects to continue receiving COBRA continuation. The Executive agrees
that, should he commence full-time employment (or employment that provides him with eligibility for healthcare benefits substantially comparable to those provided by the Company) prior to the date that is nine (9) months following the
Separation Date, he will so inform the Company in writing within five (5) business days of such commencement. 

 (b)
Consulting Agreement – On the Effective Date, the Company and the Executive shall also enter into a consulting agreement in the form attached to this Agreement as Attachment B (the “Consulting Agreement”). It is
understood that, during the Consultation Period, as defined in the Consulting Agreement, the Executive’s equity awards that vest solely based on the passage of time shall continue to vest and become free from forfeiture through the Consultation
Period, and shall remain exercisable, in accordance with the applicable award agreement(s) and equity plan(s), provided, however, that to the extent that the Executive complies with his obligations under this Agreement and the Consulting Agreement,
(i) effective as of the Expiration Date (as defined in the Consulting Agreement), the vesting of the stock option granted by the Company to Executive in February 2022 shall accelerate with respect to 50,000 unvested shares, and (ii) any
vested options granted at any time by the Company to Executive that remain outstanding at the end of the Consultation Period (including those for which vesting accelerated pursuant to the previous clause (i)) shall remain exercisable until the
earlier of (x) one (1) year following the end of the Consultation Period and (y) the original expiration date of such option, with all such options otherwise remaining subject to the terms and conditions of the applicable award
agreement(s) and equity plan(s). For the avoidance of doubt, as of the Effective Date, each such stock option shall be treated as a nonqualified stock option for tax purposes even if that option was intended to be an incentive stock option. 

Other than the Consideration and the Accrued Obligations, the Executive will not be eligible for, nor shall he have a right to receive, any
payments or benefits from the Company following the Separation Date, including, for the avoidance of doubt, any severance benefits pursuant to the Letter Agreement. 
  

	3.	 Release of Claims – In exchange for the consideration set forth in this Agreement, which the
Executive acknowledges he would not otherwise be entitled to receive, the Executive hereby fully, forever, irrevocably and unconditionally releases, remises and discharges the Company, its past and present affiliates, subsidiaries, parent companies,
predecessors, and successors, and all of its and their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their
individual and corporate capacities) (collectively, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings,
covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that the Executive ever had or now has against any or all
of the Released Parties, whether known or unknown, including, but not limited to, any and all claims arising out of 

  
 3 

	 	
or relating to the Executive’s employment with or separation from, and/or ownership of securities of the Company, including, but not limited to, all claims under Title VII of the Civil
Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff et
seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29
U.S.C. § 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq., and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C.
§ 1001 et seq., all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, § 1 et seq., the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12,
§§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen.
Laws ch. 214, § 1B (Massachusetts right of privacy law), the Massachusetts Parental Leave Act, Mass. Gen. Laws ch. 149, § 105D, the Massachusetts Paid Family and Medical Leave Act, Mass. Gen. Laws ch. 175m, § 1, et seq.,
the Massachusetts Earned Sick Time Law, Mass. Gen. Laws ch. 149, § 148c, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended; all rights and claims under the Massachusetts Wage Act, Mass. Gen.
Laws ch. 149, § 148 et seq., as amended (Massachusetts law regarding payment of wages and overtime), including any rights or claims thereunder to unpaid wages, including overtime, bonuses, commissions, and accrued, unused vacation
time; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising
out of or related to the Letter Agreement); all claims to any non-vested ownership interest in the Company, contractual or otherwise (except for any such interests that continue to vest during the Transition
Period due to the Executive’s continued employment during such period, or during the period the Executive is providing services under the Consulting Agreement); all state and federal whistleblower claims to the maximum extent permitted by law;
and any claim or damage arising out of Executive’s employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced
above; provided, however, that this release of claims shall not (i) prevent the Executive from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a
state fair employment practices agency (except that the Executive acknowledges that he may not recover any monetary benefits in connection with any such charge, investigation, or proceeding, and the Executive further waives any rights or claims to
any payment, benefit, attorneys’ fees or other remedial relief in connection with any such charge, investigation or proceeding), or (ii) deprive the Executive of any rights the Executive may have to be indemnified by the Company as
provided in any agreement between the Company and the Executive or pursuant to the Company’s Certificate of Incorporation or by-laws. 

 

	4.	 Continuing Obligations – The Executive acknowledges and reaffirms his obligation,
except as otherwise permitted by Section 8 below, both during the Transition Period and thereafter, to keep confidential and not to use or disclose any and all non-public information concerning the
Company acquired by him during the course of his employment with the Company, including, but not limited to, any non-public information concerning the Company’s business, operations, products, programs,
affairs, performance, personnel, technology, science, intellectual property, plans, strategies, approaches, prospects, financial condition or development related matters. The Executive also acknowledges all of his continuing obligations pursuant to
the Restrictive Covenant Agreement, which survive his separation from employment with the Company and shall remain in full force and effect. 

  
 4 

	5.	 Non-Disparagement– The Executive understands and
agrees that, except as otherwise permitted by Section 8 below, he will not, either during the Transition Period or thereafter, in public or private, make any false, disparaging, negative, critical, adverse, derogatory or defamatory statements,
whether orally or in writing, including online (including, without limitation, on any social media, networking, or employer review site) or otherwise, to any person or entity, including, but not limited to, any media outlet, industry group, key
opinion leader, financial institution, research analyst or current or former employee, board member, consultant, shareholder, client or customer of the Company, regarding the Company, or any of the other Released Parties that are known, or should be
known, by Executive to be Released Parties, or regarding the Company’s business, operations, products, programs, affairs, performance, personnel, technology, science, intellectual property, plans, strategies, approaches, prospects, financial
condition or development related matters. The Company will instruct its officers and all members of its Board of Directors that they shall not, either during the Transition Period or thereafter, in public or private, make any false, disparaging,
negative, critical, adverse, derogatory or defamatory statements, whether orally or in writing, to any person or entity concerning Executive; provided, however, that the foregoing shall not be construed as requiring an instruction that any person
refrain from making any statement concerning Executive in connection with any legitimate business need and/or to comply with or satisfy their or the Company’s disclosure, reporting or other obligations under applicable law.

  

	6.	 Return of Company Property – The Executive agrees that, no later than the Separation
Date (or at such earlier or later time as may be requested in writing by the Company), he will return to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers,
flash drives and other storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any other Company-owned property in his possession or control, and that he will leave intact all, and will not otherwise
not destroy, delete, or make inaccessible to the Company any, electronic Company documents, including, but not limited to, those that he developed or helped to develop during his employment. The Executive further agrees that, except as he may be
specifically instructed otherwise by the Company’s Chief Executive Officer, he will not (a) retain any copies in any form or media; (b) maintain access to any copies in any form, media, or location; (c) store any copies in any
physical or electronic locations that are not readily accessible or not known to the Company or that remain accessible to him; or (d) send, give, or make accessible any copies to any persons or entities that the Company has not authorized to
receive such electronic or hard copies. The Executive further agrees that, except as he may be specifically instructed otherwise by the Company’s Chief Executive Officer, he will, no later than the Separation Date (or at such earlier or later
time as may be requested in writing by the Company) cancel all accounts for his benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts, and computer accounts.

  

	7.	 Confidentiality – The Executive understands and agrees that, except as otherwise permitted
by Section 8 below, the contents of the negotiations and discussions resulting in this Agreement and the Additional Release shall be maintained as confidential by the Executive and his agents and representatives and shall not be disclosed
except as otherwise agreed to in writing by the Company. 

  

	8.	 Scope of Disclosure Restrictions – Nothing in this Agreement, the Additional Release, or
elsewhere prohibits the Executive from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies, filing a complaint with government agencies, or
participating in government agency investigations or proceedings. The Executive is not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information the Executive obtained
through a communication that was subject to the attorney-client privilege. 

  
 5 

	 	
Further, notwithstanding the Executive’s confidentiality and nondisclosure obligations, the Executive is hereby advised as follows pursuant to the Defend Trade Secrets Act: “An
individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court
proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.” 

 

	9.	 Cooperation – The Executive agrees that, to the extent permitted by law, he shall cooperate
fully with the Company in: (i) any internal investigation; (ii) any investigation, defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against the
Company by a third party or by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator; or (iii) any other administrative, regulatory, or
judicial inquiry, investigation, proceeding or arbitration. The Executive’s full cooperation hereunder shall include, but not be limited to, making himself available to the Company upon reasonable notice for interviews and factual
investigations; appearing at the Company’s request to give testimony without requiring service of a subpoena or other legal process; volunteering to the Company pertinent information; and turning over all relevant documents which are in or may
come into his possession. The term “cooperation” does not mean that the Executive must provide information that is favorable to the Company; it means only that the Executive will provide truthful information within his knowledge and
possession upon request of the Company. The Company will reimburse the Executive for all reasonable and documented travel expenses that he incurs at the Company’s request to comply with this paragraph and, (i) if the Company requests
cooperation hereunder after the Consultation Period has ended, (ii) such post-Consultation Period cooperation exceeds, in the aggregate, five (5) hours of Executive’s time, and (iii) the Company has requested such additional
hours of cooperation in writing, compensate Executive for such additional hours at the rate of three hundred and fifty dollars ($350.00) per hour; provided, however, that the Company will not compensate Executive for any time spent testifying in any
arbitration, trial, judicial proceeding, administrative hearing or other proceeding. The Executive further agrees that, to the extent permitted by law, he will notify the Company promptly in the event that he is served with a subpoena (other
than a subpoena issued by a government agency), or in the event that he is asked to provide a third party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company.

  

	10.	 Amendment and Waiver – This Agreement and the Additional Release, upon their
respective effective dates, shall be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Parties. This Agreement and the
Additional Release are binding upon and shall inure to the benefit of the Parties and their respective agents, assigns, heirs, executors/administrators/personal representatives, and successors. No delay or omission by the Company in exercising any
right under this Agreement or the Additional Release shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to
or waiver of any right on any other occasion. 

  
 6 

	11.	 Validity – Should any provision of this Agreement or the Additional Release be declared or
be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a
part of this Agreement or the Additional Release. 

  

	12.	 Nature of Agreement – Both Parties understand and agree that this Agreement,
including the Additional Release, is a transition, separation and release of claims agreement and does not constitute an admission of liability or wrongdoing on the part of the Company or the Executive. 

 

	13.	 Acknowledgments – The Executive acknowledges that he was initially presented with
this Agreement on December 2, 2022 (the “Receipt Date”). The Executive acknowledges that he has been given a reasonable amount of time to consider this Agreement, and at least
twenty-one (21) days from the Receipt Date to consider the Additional Release (such 21-day period, the “Consideration Period”), and that the
Company is hereby advising him to consult with an attorney of his own choosing prior to signing this Agreement and the Additional Release. The Executive further acknowledges and agrees that any changes made to this Agreement, the Additional Release,
or any exhibits or attachments hereto following his initial receipt of such documents on the Receipt Date, whether material or immaterial, shall not re-start or affect in any manner the Consideration Period.
The Executive understands that he may revoke the Additional Release for a period of seven (7) days after he signs it by notifying the Company in writing, and that the Additional Release shall not be effective or enforceable until the expiration
of the seven (7) day revocation period (the day immediately following expiration of such revocation period, the “Additional Release Effective Date”). The Executive understands and agrees that by entering into the Additional
Release he will be waiving any and all rights or claims he might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that he will have received consideration beyond that to which he was
previously entitled. The Executive further understands that he will not be eligible to receive the Consideration unless he timely signs, returns, and does not revoke the Additional Release.

 

	14.	 Voluntary Assent – The Executive affirms that no other promises or agreements of any
kind have been made to or with the Executive by any person or entity whatsoever to cause him to sign this Agreement, and that he fully understands the meaning and intent of this Agreement and that he has had the opportunity to consult with counsel
of his own choosing. The Executive further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free
act. 

  

	15.	 Governing Law – This Agreement and the Additional Release shall be interpreted and construed
by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions. Each of the Company and the Executive hereby irrevocably submits to and acknowledges and recognizes the exclusive jurisdiction and venue of the courts
of the Commonwealth of Massachusetts, or if appropriate, the United States District Court for the District of Massachusetts (which courts, for purposes of this Agreement and the Additional Release, are the only courts of competent jurisdiction),
over any suit, action or other proceeding arising out of, under or in connection with this Agreement and the Additional Release or the subject matter thereof. 

 

	16.	 Entire Agreement – This Agreement, including the Additional Release, the Consulting
Agreement, and the Restrictive Covenant Agreement, contain and constitute the entire understanding and agreement between the Parties hereto with respect to the Executive’s transition and separation from the Company, and the settlement of claims
against the Company, and cancels all previous oral and written negotiations, agreements, commitments and writings in connection therewith, including, without limitation, the Letter Agreement. 

  
 7 

	17.	 Tax Acknowledgement – The Company shall have the right to withhold and remit to the
applicable tax authorities any amounts it believes are required to be withheld by the Company under applicable law (including, without limitation, any amounts required to comply with Swiss tax law). Notwithstanding the foregoing, the Executive shall
be solely responsible for any self-assessment and remittance of Swiss social security, Swiss income, or other U.S., Swiss, or other taxes. The Executive acknowledges that he is not relying upon the advice or representation of the Company with
respect to the tax treatment of any payments made by the Company to the Executive. The Executive further agrees and acknowledges that he shall indemnify and hold harmless the Company with respect to any Swiss taxes and/or tax liability (including,
without limitation, social security, income, and employment related taxes) that may arise for the Executive or the Company as a result of his residency and performance of services in Switzerland, whether pursuant to this Agreement or the Consulting
Agreement attached as Attachment B, including, for the avoidance of doubt, with respect to the vesting and/or exercise of Company stock options or other equity awards. 

 

	18.	 Counterparts – This Agreement and the Additional Release may be executed in several
counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Facsimile and PDF signatures shall be deemed to be of equal force and effect as originals. 

[Remainder of page intentionally left blank] 

  
 8 

 IN WITNESS WHEREOF, the Parties have set their hands and seals to this Agreement as of the date(s) written
below. 
 INOZYME PHARMA, INC. 
  

									
	By:    	 	 /s/ Axel Bolte
	 		 		 	Date: 12/7/2022
	Name:	 	Axel Bolte	 		 		 	
	Title:	 	President and Chief Executive Officer	 		 		 	

 I hereby agree to the terms and conditions set forth above. I have been given a reasonable amount of time to consider this
Agreement and I have chosen to execute this on the date below. I further understand that my receipt of the Consideration is contingent upon my timely execution, return and non-revocation of the Additional
Release, and that I have been given at least twenty-one (21) days to consider such Additional Release and will have seven (7) days in which to revoke my acceptance after I sign such Additional
Release. 
 HENRIC BJARKE 
  

					
	 /s/ Henric Bjarke
	 		 	 Date: 12/7/2022

 [Signature Page to Transition, Separation and Release of Claims Agreement] 

 ATTACHMENT A 

ADDITIONAL RELEASE OF CLAIMS 
  

This Additional Release of Claims (this “Additional Release”) is made by the Executive as of the date set forth opposite his
signature below. Capitalized terms used but not defined herein have the meanings set forth in the Executive Transition, Separation, and Release of Claims Agreement to which this Additional Release is attached as Attachment A (the
“Agreement”). 
 WHEREAS, the Executive’s Separation Date has occurred on or prior to the execution of this
Additional Release; and 
 WHEREAS, the Executive is entering into this Additional Release in accordance with the terms and
conditions set forth in the Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in the
Agreement and herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Executive hereby agrees as follows: 

1. Release – In exchange for the Consideration set forth in the Agreement, which the Executive acknowledges he would not otherwise be
entitled to receive, the Executive hereby fully, forever, irrevocably and unconditionally releases, remises and discharges the Company, its past and present affiliates, subsidiaries, parent companies, predecessors, and successors, and all of its and
their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively,
the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings,
omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that the Executive ever had or now has against any or all of the Released Parties, whether known or unknown,
including, but not limited to, any and all claims arising out of or relating to Executive’s employment with or separation from, and/or ownership of securities of the Company, including, but not limited to, all claims under Title VII of the
Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq.,
the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act
(“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et
seq., and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch.
151B, § 1 et seq., the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the
Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy law), the Massachusetts Parental Leave Act, Mass. Gen. Laws ch. 149, § 105D, the
Massachusetts Paid Family and Medical Leave Act, Mass. Gen. Laws ch. 175m, § 1, et seq., the Massachusetts Earned Sick Time Law, Mass. Gen. Laws ch. 149, § 148c, and the Massachusetts Small Necessities Leave Act, Mass. Gen.
Laws ch. 149, § 52D, all as amended; all rights and claims under the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 et seq., as amended (Massachusetts law regarding payment of wages and overtime), including any rights
or claims thereunder to unpaid wages, including overtime, bonuses, commissions, and accrued, unused vacation time; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress,
misrepresentation, fraud, wrongful discharge, and breach of 

 
contract; all claims to any non-vested ownership interest in the Company, contractual or otherwise (except for any such interests that continue to vest
during the period the Executive is providing services under the Consulting Agreement); all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of the Executive’s employment with
and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that this release of claims shall not
(i) prevent the Executive from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency (except that the
Executive acknowledges that he may not recover any monetary benefits in connection with any such charge, investigation, or proceeding, and the Executive further waives any rights or claims to any payment, benefit, attorneys’ fees or other
remedial relief in connection with any such charge, investigation or proceeding), or (ii) deprive the Executive of any rights the Executive may have to be indemnified by the Company as provided in any agreement between the Company and the
Executive or pursuant to the Company’s Certificate of Incorporation or by-laws. 
 2. Return of Company
Property – The Executive confirms that, except as he has been specifically instructed otherwise by the Company’s Chief Executive Officer, he has returned to the Company all keys, files, records (and copies thereof),
equipment (including, but not limited to, computer hardware, software, printers, flash drives and other storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any other Company-owned property in his
possession or control, and that he has left intact all, and has otherwise not destroyed, deleted, or made inaccessible to the Company any, electronic Company documents, including, but not limited to, those that he developed or helped to develop
during his employment. The Executive further confirms that, except as he has been specifically instructed otherwise by the Company’s Chief Executive Officer, he has not (a) retained any copies in any form or media; (b) maintained
access to any copies in any form, media, or location; (c) stored any copies in any physical or electronic locations that are not readily accessible or not known to the Company or that remain accessible to him; or (d) sent, given, or made
accessible any copies to any persons or entities that the Company has not authorized to receive such electronic or hard copies. The Executive further confirms that, except as he has been specifically instructed otherwise by the Company’s Chief
Executive Officer, he has canceled all accounts for his benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts, and computer accounts. 

3. Business Expenses; Final Compensation – The Executive acknowledges that he has been reimbursed by the Company for all business expenses
incurred in conjunction with the performance of his employment and that no other reimbursements are owed to him. The Executive further acknowledges that he has received all compensation due to him from the Company, including, but not limited to, all
wages, bonuses and accrued, unused vacation time, and that he is not eligible or entitled to receive any additional payments or consideration from the Company beyond the Consideration. 

4. Time for Consideration; Acknowledgments – The Executive acknowledges that, in order to receive the Consideration, he must sign and return
this Additional Release no earlier than the Separation Date but by the later of the Separation Date and the twenty-second (22nd) day after the Receipt Date and he must continue to comply with his
obligations under the Restrictive Covenant Agreement. The Executive acknowledges that he has been given at least twenty-one (21) days to consider this Additional Release, and that the Company advised him
to consult with an attorney of his own choosing prior to signing this Additional Release. The Executive understands that he may revoke this Additional Release for a period of seven (7) days after he signs it by notifying the Company in writing,
and the Additional Release shall not be effective or enforceable until the expiration of this seven (7) day revocation period. In the event the Executive executes this Additional Release after the Separation Date but prior to the twenty-second
(22nd) day after the Receipt Date, he acknowledges that such decision is entirely voluntary and that he has had the opportunity to consider such release until the end of the twenty-one (21) day period. The Executive 

  
 - 2 - 

 
understands and agrees that by entering into this Additional Release, he is waiving any and all rights or claims he might have under the Age Discrimination in Employment Act, as amended by the
Older Workers Benefit Protection Act, and that he has received consideration beyond that to which he was previously entitled. For the avoidance of doubt, this Additional Release supplements, and in no way limits, the Agreement. 

5. Voluntary Assent – The Executive affirms that no other promises or agreements of any kind have been made to or with him by any person or
entity whatsoever to cause him to sign this Additional Release, and that he fully understands the meaning and intent of this Additional Release. The Executive states and represents that he has had an opportunity to fully discuss and review the terms
of this Additional Release with an attorney. The Executive further states and represents that he has carefully read this Additional Release, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof,
and signs his name of his own free act. The Executive hereby provides this Additional Release as of the date below and acknowledges that he will not be entitled to receive the Consideration set forth in the Agreement unless this Additional Release
becomes effective and enforceable. 
 I hereby provide this Additional Release as of the current date and acknowledge that the execution of this
Additional Release is in further exchange for the Consideration, to which I acknowledge I would not be entitled if I did not enter into this Additional Release. I intend that this Additional Release will become a binding agreement between me and the
Company if I do not revoke my acceptance in seven (7) days. 
  

					
	HENRIC BJARKE	 		 	
	  
	 		 	Date: ____________________

 To be signed and returned no earlier than the Separation Date but by the later of the Separation Date and the twenty-second
(22nd) day after the Receipt Date. 

  
 - 3 - 

 ATTACHMENT B 

CONSULTING AGREEMENT 

Incorporated by reference to Exhibit 10.2 of this Current Report on Form 8-K filed with the
Securities Exchange Commission on December 8, 2022 

  
 - 4 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]